Take-at-home drug can ‘disarm' cancer
The drug, known as KCL-HO-1i, works by disarming a defence mechanism that tumours use to protect themselves. Early tests on mice found the drug even helped chemotherapy-resistant tumours to respond to treatment.
It is hoped KCL-HO-1i can be trialled on humans, with researchers suggesting it could one day be a 'valuable companion drug' to chemotherapy, helping patients to avoid more aggressive treatments.
Chemotherapy is used to treat many kinds of cancer and works by disrupting the way cancer cells grow and divide. However, it is not as effective as it should be in some patients because the body's own immune cells can act as a barrier around tumours.
These cells produce a protein called heme oxygenase-1 (HO-1), which helps shield the tumour from the immune system and block the effects of chemotherapy.
Exciting step forward
KCL-HO-1i, created at King's College London (KCL), targets this protein to make tumours more responsive to treatment.
Prof James Arnold, the head of the tumour immunology group at the university, said it discovered the cells responsible for protecting the body's immune system 'play a key role in blocking chemotherapy'.
|He said: 'By targeting the enzyme they produce using KCL-HO-1i, we were able to help beneficial immune cells and chemotherapy drugs become significantly more effective.
'In laboratory models, even chemotherapy-resistant tumours became responsive to treatment, which is a really exciting step forward.'
The drug has been designed for patients to take at home as a tablet between chemotherapy sessions.
Early tests on mice, with the results published in the journal Science Translational Medicine, found the drug made breast cancer tumours more responsive to different types of chemotherapy.
Researchers are now hopeful that trials involving patients with breast cancer and other forms of the disease could begin within two years.
James Spicer, a professor of experimental cancer medicine at KCL, said: 'Chemotherapy remains a key part of treatment for many patients with cancer, but too often it is not as effective or long-lasting as we might like.
'This research has identified a key reason for these limitations, and discovered a drug that we are keen to test in the clinic alongside established chemotherapy drugs.'
Miraz Rahman, a professor of medicinal chemistry at KCL, added: 'If human trials are successful, KCL-HO-1i could become a valuable companion drug to existing cancer therapies – helping more patients to benefit from the treatments that are already available and reduce the need for more aggressive cancer therapies in the future.'
The King's College London scientists have launched a spin-out company called Aethox Therapeutics.
Tanya Hollands, the research information manager at Cancer Research UK, which supported the study alongside funding from the Medical Research Council, said: 'Researchers are increasingly learning how to make better use of existing cancer treatments, whether it's using them differently or in combination with new medicines, like this work suggests.
'Using combination therapies can help bring improved treatment options to patients more quickly, safely and affordably, because some components of the treatment have already been tested and used in the clinic.
'While early stage, it's exciting to see this potential new way to disarm cancer's ability to avoid detection by the immune system with a new drug, while also boosting the effectiveness of chemotherapy, and we look forward to seeing how this work progresses.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
3 hours ago
- The Guardian
Abortion drug could help reduce risk of breast cancer, group of medics says
A drug used in medical abortions could help prevent women at high risk of breast cancer from developing the disease, according to an international group of doctors and scientists. However, 'stigma' around mifepristone is stopping pharmaceutical companies from investigating its potential as a new treatment doctors could offer to reduce the risk of breast cancer, they say. Companies appear reluctant to carry out trials despite the fact that three previous studies all found that the drug shows promise as a way of slowing down the growth of cancerous cells. Mifepristone's role in medical abortions and fact that access to abortion is restricted in some countries is preventing much-needed research being done, the experts claim. It is one of two drugs, alongside misoprostol, that women in the UK take when ending a pregnancy that began up to 10 weeks earlier. They take a mifepristone tablet, then wait for 24-48 hours and then take the misoprostol. 'It is deeply disappointing that the successful application of mifepristone in one area of clinical medicine is hindering more extensive research into other indications that could benefit public health,' the opinion piece written by eight co-authors and published in The Lancet Obstetrics, Gynaecology and Women's Health says. All are experts in reproductive health or reproductive cancer working in London, Edinburgh, Stockholm and Erbil in Iraq. 'The time is long overdue to give mifepristone the opportunity it deserves to be investigated as a non-surgical option for primary prevention [of breast cancer],' they add. Breast cancer is the most common female cancer in most countries in the world and kills an estimated 670,000 women globally every year, according to the World Health Organization. Although small-scale, the three previous studies offered evidence mifepristone can limit the effect of the hormone progesterone, which drives the cell growth found in breast cancer. They were published in 2008, 2022 and 2024. Mifepristone is a type of drug known as a selective progesterone receptor modulator. If proven to work, it could help women who are at high risk of breast cancer, such as those who carry a variant of the BRCA1 or BRCA2 genes. Currently they are offered surgical options for their treatment, such as a mastectomy, or drugs that are of 'low efficacy', the authors say. UK cancer charities endorsed the plea for drug companies to look seriously into the role mifepristone could play in breast cancer care and for governments to enable that to happen by easing regulations that restrict its use to abortion. Dr Simon Vincent, the chief scientific officer at Breast Cancer Now, said: 'More risk-reducing treatment options for women with a high risk of developing breast cancer, that also protects their quality of life, are desperately needed. And we need to explore all avenues, including existing drugs, to achieve this. 'So early research into mifepristone is an important step forward and we need further studies to understand if these drugs are safe and effective.' Dr Marianne Baker, Cancer Research UK's science engagement manager, said the 57,900 new diagnoses a year of breast cancer in Britain showed that 'it's vital we invest in research exploring new ways to prevent the disease'. She added: 'Cancer develops when cells grow uncontrollably. Early studies showed that mifepristone slowed down cell growth in breast tissue, so it might be useful in delaying or preventing cancer. 'But we need more research to understand whether it's effective, how it works and who would benefit most from it.' Prof Kristina Gemzell Danielsson, the piece's lead author, and who heads the department of women's and children's health at the Karolinska Institute in Stockholm, said: 'Stigma around mifepristone used for abortion is describing part of why mifepristone is not more extensively researched for prevention of breast cancer. 'Taken together, our data support the use of mifepristone for prevention of poor prognosis breast cancer. All studies were randomised controlled trials using a low dose of mifepristone for two or three months.'
Times
4 hours ago
- Times
Brain chip could translate thoughts into speech
Technology with the ability to decode a person's inner thoughts and translate them into speech in real time has moved a step closer after the testing of a new brain implant, scientists have claimed. Researchers at Stanford University in California said that their device was able, with 74 per cent accuracy, to detect a person's 'inner speech' — where they imagined saying a specified set of words in their mind without any effort to physically utter them — and decipher which words they were thinking about. They said that it could represent a breakthrough for people with various forms of paralysis or impairments that prevent them from speaking unaided and could one day 'restore communication that is as fluent, natural and comfortable as conversational speech'.
The Independent
5 hours ago
- The Independent
Nike co-founder Phil Knight and wife give record $2B to Oregon cancer center, university says
Nike co-founder Phil Knight and his wife Penny Knight have pledged to donate $2 billion to Oregon Health & Science University's Knight Cancer Institute, the university announced Thursday, describing it as a record-breaking gift. 'This gift is an unprecedented investment in the millions of lives burdened with cancer, especially patients and families here in Oregon,' OHSU President Shereef Elnahal said in a statement. The donation will help ensure patients have access to various resources, including psychological, genetic and financial counseling, symptom management, nutritional support and survivorship care, the university statement said. 'We couldn't be more excited about the transformational potential of this work for humanity,' the Knights said in the statement. The university described it as the 'largest single donation ever made to a U.S. university, college or academic health center.' It surpasses the $1.8 billion given by Michael Bloomberg to Johns Hopkins in 2018, described by that university at the time as the largest single contribution to a U.S. university. Bloomberg also donated an additional $1 billion to Johns Hopkins last year, covering tuition, living expenses and fees for students from families under certain income levels. The magnitude of the donation will allow the Knight Cancer Institute to become a self-governed entity with its own board of directors within OHSU, the university said. Knight, Oregon's richest man, donated $500 million to the cancer institute in 2013 on the condition the gift be matched within two years.
